Endocrine Abstracts (2006) 11 OC20

A European prospective real-life observational study of Quality of Life in patients with acromegaly

SM Webb1, A Colao2, P Caron3, M Carvalheiro4, E Ertürk5, A Pokrajac-Simeunovic6, J Schopohl7, S Tsagarakis8, IV Pearson9, X Badia10, S Caglio11 & B Vincenzi11


1Servicio de Endocrinología, Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; 2Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Naples, Italy; 3Department of Endocrinology and Metabolism Disease, Centre Hospitalier de Rangueil, Toulouse Cedex, France; 4Hospitais da Universidade de Coimbra, Serviço de Endocrinologia, Coimbra, Portugal; 5Department of Endocrinology and Metabolism, Uludag University Medical Faculty, Bursa, Turkey; 6Department of Endocrinology, Christie Hospital, Manchester, United Kingdom; 7Endokrinologisches Zentrum, Medizinische Klinik, Klinikum der LMU, Munich, Germany; 8Department of Endocrinology, Polykliniki of Athens Hospital, Athens, Greece; 9Evidence Research Unit, Macclesfield, Cheshire, United Kingdom; 10Health &br;Outcomes Research Europe, Barcelona, Spain; 11Novartis Oncology, Region Europe, Origgio, Italy.


The primary aim of this study, the largest European, single evaluation, observational trial to date, was to evaluate the impact of acromegaly on health-related quality of life (HRQoL) in patients with biochemically documented active disease, receiving Sandostatin® LAR® at a dose prescribed by their physician for at least 3 months. Secondary objectives were to investigate the relationships between HRQoL and subpopulations based on exploratory variables [age, gender, education, growth hormone (GH) and insulin-like growth factor (IGF-1)] and to compare the results of the Acromegaly Quality-of-Life questionnaire (ACROQOL) and SF-36. The study was approved by Health Authorities and/or local Ethics Committees, according to local regulations. Patients were invited to participate in the study when they attended a scheduled visit. GH and IGF-1 levels were to be measured within two months of completion of the questionnaires.

A total of 817 patients (55% female, mean age 51±14 years) were recruited in England, France, Germany, Greece, Italy, Portugal, Spain and Turkey. Patients had a diagnosis of acromegaly for an average of 8 years, and had been treated with Sandostatin® LAR® for an average of 3.4 years (range 0.3–18 years) at a median dose of 30 mg (range 10–60 mg). Basal GH and IGF-1 mean levels were 4.2 and 345 ng/ml respectively. Both the ACROQOL and SF-36 recorded poorer HRQoL with advancing age and increasing number of comorbidities. The correlation between the ACROQOL and the SF-36 was good (P<0.001) and overall results suggest that ACROQOL may be more sensitive to the psychological impact of acromegaly than to the physical impact. While some cultural differences were found across the SF-36 domains, the results with the ACROQOL were consistent across all countries, confirming the ACROQOL to be a valid and sensitive tool for measuring the impact of acromegaly on HRQoL.